Antibiotic

Kaleido Biosciences Announces Collaboration with Robert Jenq, M.D., to Explore Potential of its Microbiome Metabolic Therapies (MMT™) in Preventing Febrile Neutropenia

Retrieved on: 
Tuesday, April 20, 2021
Medical specialties, Branches of biology, Anatomy, Autoimmune diseases, Antibiotic, Broad-spectrum antibiotic, Neutropenia, Microbiome

This may lead to significant side effects including severe damage to the gut epithelium, and major disruption to a patient\xe2\x80\x99s microbiome,\xe2\x80\x9d said Johan van Hylckama Vlieg, Chief Scientific Officer at Kaleido Biosciences.

Key Points: 
  • This may lead to significant side effects including severe damage to the gut epithelium, and major disruption to a patient\xe2\x80\x99s microbiome,\xe2\x80\x9d said Johan van Hylckama Vlieg, Chief Scientific Officer at Kaleido Biosciences.
  • \xe2\x80\x9cAdditionally, treatment combinations with broad-spectrum antibiotics used in the conditioning process, leave patients increasingly more susceptible to neutropenic fever.
  • These human clinical studies are conducted under regulations supporting research with food, evaluating safety, tolerability and potential markers of effect.
  • Kaleido is advancing a broad pipeline of MMT candidates with the potential to address a variety of diseases and conditions with significant unmet patient needs.

OpGen Extends and Expands Partnership with New York State Department of Health to Detect Antimicrobial-Resistant Infections

Retrieved on: 
Monday, April 19, 2021
Articles, Health sciences, Evolutionary biology, Pharmaceuticals policy, Veterinary medicine, XC2, Antimicrobial resistance, Antimicrobial, Life sciences, Antibiotic

\xe2\x80\x9cThe quick spread of antimicrobial resistant superbugs across healthcare systems is the silent pandemic hidden underneath the current COVID-19 pandemic.

Key Points: 
  • \xe2\x80\x9cThe quick spread of antimicrobial resistant superbugs across healthcare systems is the silent pandemic hidden underneath the current COVID-19 pandemic.
  • Together, these products can help to rapidly identify and locate antibiotic resistance threats in healthcare institutions and networks.
  • Victory Derbyshire\xc2\xa0said,\xc2\xa0\xe2\x80\x9cUnder Governor Cuomo\'s leadership New York State\xc2\xa0continues to lead the nation in addressing the threat of antimicrobial resistance.
  • The Center serves a vital role in the\xc2\xa0New York State Department\xc2\xa0of Health\xe2\x80\x99s efforts to protect and promote the health of New York\xe2\x80\x99s citizens.

Phico Therapeutics Awarded up to $18.2 Million USD (c.£13.2 Million GBP) CARB-X Funding to Advance SASPject Antibacterial Therapy Through Phase 1 Clinical Trials

Retrieved on: 
Monday, April 19, 2021
Science, Biotechnology, Research, Pharmaceutical, Health, Infectious diseases, Hospitals, Clinical trials, Health sciences, Medical specialties, Medicine, Evolutionary biology, Pharmaceuticals policy, Veterinary medicine, Antimicrobial resistance, Drug resistance, XC2, Antibiotic, Bacteria

\xc2\xa313.2 million GBP) from Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), a global non-profit partnership dedicated to accelerating antibacterial research to tackle the global rising threat of drug-resistant bacteria.

Key Points: 
  • \xc2\xa313.2 million GBP) from Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), a global non-profit partnership dedicated to accelerating antibacterial research to tackle the global rising threat of drug-resistant bacteria.
  • The funding will support the progression of Phico\xe2\x80\x99s lead product SASPject\xe2\x84\xa2 PT3.9 through clinical trials with $5.3 million USD (circa.
  • \xc2\xa33.8 million GBP) available immediately and a further $12.9 million (circa.
  • Heather Fairhead, Phico Founder and CEO said: \xe2\x80\x9cTo receive funding from CARB-X is important validation for our SASPject technology platform and its potential in fighting bacterial resistance.

Companion Animal Pharmaceuticals Market worth $18.5 billion by 2026 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Monday, April 12, 2021
Health sciences, Lincosamides, Antimicrobial, Infection, Antibiotic, Life sciences, Health, Antibiotic resistance, Pharmaceuticals policy, Veterinary medicine

b'The growth in this market is majorly driven by the growth in companion animal ownership, rising prevalence of zoonotic diseases, rising demand for pet insurance with the growing animal health expenditure, and initiatives by various government agencies and animal associations.

Key Points: 
  • b'The growth in this market is majorly driven by the growth in companion animal ownership, rising prevalence of zoonotic diseases, rising demand for pet insurance with the growing animal health expenditure, and initiatives by various government agencies and animal associations.
  • The infectious diseases segment accounted for the largest share of the market.
  • The veterinary hospitals segment holds the largest share in the companion animal pharmaceuticals market due to the higher adoption of animal parasiticides and antibiotics in hospital settings, increasing incidence of infectious diseases, growing number of veterinary hospitals, growing ownership of companion animals, increasing veterinary expenditure, and growing awareness about animal health in developing countries.\nThe companion animal pharmaceuticals market in the APAC region is expected to register the highest CAGR during the forecast period.
  • Ltd. (India).\nAnimal Antibiotics and Antimicrobials Market by Product (Tetracycline, Penicillin, Sulfonamide, Macrolide, Cephalosporin, Lincosamide), Mode of Delivery (Premixes, Oral Solution, Injection), Animal (Food producing & Companion) - Global Forecast to 2026\n'

Companion Animal Pharmaceuticals Market worth $18.5 billion by 2026 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Monday, April 12, 2021
Health sciences, Lincosamides, Antimicrobial, Infection, Antibiotic, Life sciences, Health, Antibiotic resistance, Pharmaceuticals policy, Veterinary medicine

b'The growth in this market is majorly driven by the growth in companion animal ownership, rising prevalence of zoonotic diseases, rising demand for pet insurance with the growing animal health expenditure, and initiatives by various government agencies and animal associations.

Key Points: 
  • b'The growth in this market is majorly driven by the growth in companion animal ownership, rising prevalence of zoonotic diseases, rising demand for pet insurance with the growing animal health expenditure, and initiatives by various government agencies and animal associations.
  • The infectious diseases segment accounted for the largest share of the market.
  • The veterinary hospitals segment holds the largest share in the companion animal pharmaceuticals market due to the higher adoption of animal parasiticides and antibiotics in hospital settings, increasing incidence of infectious diseases, growing number of veterinary hospitals, growing ownership of companion animals, increasing veterinary expenditure, and growing awareness about animal health in developing countries.\nThe companion animal pharmaceuticals market in the APAC region is expected to register the highest CAGR during the forecast period.
  • Ltd. (India).\nAnimal Antibiotics and Antimicrobials Market by Product (Tetracycline, Penicillin, Sulfonamide, Macrolide, Cephalosporin, Lincosamide), Mode of Delivery (Premixes, Oral Solution, Injection), Animal (Food producing & Companion) - Global Forecast to 2026\n'

Mass General Brigham Physicians Call for Elimination of Harmful Language in Clinical Medicine

Retrieved on: 
Friday, April 9, 2021
Chemistry, Health sciences, Physical sciences, Total synthesis, Vancomycin, Johns Hopkins School of Medicine, Antibiotic, Racism, Syndrome

The article focuses on terminology used to describe a drug reaction to Vancomycin, the most commonly used antibiotic in U.S. hospitals.

Key Points: 
  • The article focuses on terminology used to describe a drug reaction to Vancomycin, the most commonly used antibiotic in U.S. hospitals.
  • Santiago AlvarezArango, MD, allergy specialist and Clinical Pharmacology Fellow at Johns Hopkins School of Medicine, was the first author of both that prior study and this perspective.
  • They propose five critical steps to achieving this goal:
    Physicians need to stop teaching Red Man Syndrome and using it in clinical practice.
  • The elimination of harmful terminology like Red Man Syndrome is consistent with Mass General Brighams United Against Racism strategic initiative ,a commitment to eliminate the many impacts that racism has on patients and employees within the Mass General Brigham system.

Autogenous Vaccines Market is predicted to witness an impressive CAGR of 5.5% over the forecast period (2021-2031)- Persistence Market Research

Retrieved on: 
Thursday, April 8, 2021
Medical specialties, Virology, Medicine, Clinical medicine, Autogenous vaccines, Vaccines, Vaccine, Antibiotic, Mycoplasma, Bacteria

Salmonella, Staphylococcus, Haemophilus, and Mycoplasma are some of the commonly used bacterial strains to develop autogenous bacterial vaccines.

Key Points: 
  • Salmonella, Staphylococcus, Haemophilus, and Mycoplasma are some of the commonly used bacterial strains to develop autogenous bacterial vaccines.
  • According to a revised report published by Persistence Market Research, the autogenous vaccines market was valued over US$ 116 Mn in 2020, and is predicted to witness an impressive CAGR of 5.5% over the forecast period (2021-2031).
  • By type of strain, bacterial autogenous vaccines are expected to contribute to more than 1/3 revenue share in the market.
  • Request for Sample PDF of Report: https://www.persistencemarketresearch.com/samples/29491
    "Increasing preference for autogenous vaccines over antibiotics will catalyze market growth over the coming years," says an analyst of Persistence Market Research.

Autogenous Vaccines Market is predicted to witness an impressive CAGR of 5.5% over the forecast period (2021-2031)- Persistence Market Research

Retrieved on: 
Thursday, April 8, 2021
Medical specialties, Virology, Medicine, Clinical medicine, Autogenous vaccines, Vaccines, Vaccine, Antibiotic, Mycoplasma, Bacteria

Salmonella, Staphylococcus, Haemophilus, and Mycoplasma are some of the commonly used bacterial strains to develop autogenous bacterial vaccines.

Key Points: 
  • Salmonella, Staphylococcus, Haemophilus, and Mycoplasma are some of the commonly used bacterial strains to develop autogenous bacterial vaccines.
  • According to a revised report published by Persistence Market Research, the autogenous vaccines market was valued over US$ 116 Mn in 2020, and is predicted to witness an impressive CAGR of 5.5% over the forecast period (2021-2031).
  • By type of strain, bacterial autogenous vaccines are expected to contribute to more than 1/3 revenue share in the market.
  • Request for Sample PDF of Report: https://www.persistencemarketresearch.com/samples/29491
    "Increasing preference for autogenous vaccines over antibiotics will catalyze market growth over the coming years," says an analyst of Persistence Market Research.

Antibiotic Alternatives Stimulate New Product Development in Global Animal Feed Ingredient Market

Retrieved on: 
Thursday, April 8, 2021
Health sciences, Livestock, Health, Branches of biology, Antibiotic resistance, Meat industry, Pharmaceuticals policy, Veterinary medicine, Antibiotic use in livestock, Probiotic, Animal feed, Antibiotic

For further information on Global Animal Feed Ingredient Market Powered by Antibiotic Alternatives and Vertical Integration, please visit: http://frost.ly/5fc

Key Points: 
  • For further information on Global Animal Feed Ingredient Market Powered by Antibiotic Alternatives and Vertical Integration, please visit: http://frost.ly/5fc
    "Amino acids dominate the global industry and are expected to remain in the top position, generating revenues of $11.5 billion by 2026.
  • The ever-growing demand for high-quality meat has forced livestock farmers to also fortify animal feed with vitamins, organic acids, enzymes, and probiotics.
  • "As farmers gradually reduce and discontinue the use of antibiotic growth promoters, the rising demand for its alternatives creates new revenue streams for manufacturers in this space."
  • Global Animal Feed Ingredient Market Powered by Antibiotic Alternatives and Vertical Integration is the latest addition to Frost & Sullivan's Chemicals, Materials and Nutrition research and analyses available through the Frost & Sullivan Leadership Council, which helps organizations identify a continuous flow of growth opportunities to succeed in an unpredictable future.

Antibiotic Alternatives Stimulate New Product Development in Global Animal Feed Ingredient Market

Retrieved on: 
Thursday, April 8, 2021
Health sciences, Livestock, Health, Branches of biology, Antibiotic resistance, Meat industry, Pharmaceuticals policy, Veterinary medicine, Antibiotic use in livestock, Probiotic, Animal feed, Antibiotic

For further information on Global Animal Feed Ingredient Market Powered by Antibiotic Alternatives and Vertical Integration, please visit: http://frost.ly/5fc

Key Points: 
  • For further information on Global Animal Feed Ingredient Market Powered by Antibiotic Alternatives and Vertical Integration, please visit: http://frost.ly/5fc
    "Amino acids dominate the global industry and are expected to remain in the top position, generating revenues of $11.5 billion by 2026.
  • The ever-growing demand for high-quality meat has forced livestock farmers to also fortify animal feed with vitamins, organic acids, enzymes, and probiotics.
  • "As farmers gradually reduce and discontinue the use of antibiotic growth promoters, the rising demand for its alternatives creates new revenue streams for manufacturers in this space."
  • Global Animal Feed Ingredient Market Powered by Antibiotic Alternatives and Vertical Integration is the latest addition to Frost & Sullivan's Chemicals, Materials and Nutrition research and analyses available through the Frost & Sullivan Leadership Council, which helps organizations identify a continuous flow of growth opportunities to succeed in an unpredictable future.